FDA Grants Datopotamab Deruxtecan Approval for ...

By Rene Pretorius

January 24, 2025

The FDA approved datopotamab deruxtecan (Datrow...
Trump Healthcare Policy Changes: Reversing Biden’s Executive Orders and...
U.S. Withdraws from WHO: Impact on Global Health Security and Relations
Medicare Drug Negotiations Target Ozempic and Ibrance for Price Cuts
Pharmaceutical Data Collaboration Between Canada’s Drug Agency and CIHI
Promising Results for Imlunestrant in Advanced ER+ HER2- Breast Cancer
CMS Price Negotiations: Bridging the Gap in US Drug Pricing
Access to Anti-Obesity Medication for Medicare and Medicaid
Zepbound Outperforms Wegovy in Weight Loss Trial
Canada’s Drug Agency Launches Consultation on New Methods Guide for Hea...
Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Pract...
Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA
Enhancing Rare Disease Decision-Making Through Integrated Data Linkage in Canada